Valproic acid-induced encephalopathy;Enzephalopathien durch valproat

Fortschritte der Neurologie Psychiatrie

Volumn 67, Issue 1, 1999, Pages 7-11

  Gobel R ^a   Gortzen A ^b   Braunig P ^b  

^a ST JOSEF HOSPITAL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; CITRULLINE; VALPROIC ACID;

ADULT; ARTICLE; BRAIN DISEASE; CASE REPORT; DRUG BLOOD LEVEL; HUMAN; INTOXICATION; MALE; SOMNOLENCE;

EID: 0344457360     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-993732     Document Type: Article

References (58)

1. Aguglia, U., A. Gambardella, M. Zappia, P. Valentino: Negative myoclonus during valproate-related stupor. Neurophysiological evidence of a cortical non-epileptic origin. Electroencephalogr. Clin. Neurophysiol. 94 (2) (1995) 103-108
2. Averbuch-Heller, L., T. Ben-Hur, A. Reches: Valproate encephalopathy and hypocarnaetinaemia in diabetic patients. J. Neurol. 241 (1994) 567-569
3. Baganz, M. D., P. E. Dross: Valproic acid-induced hyperammonemic encephalopathy. Am. J. Neuroradiol. 15 (9) (1994) 1779-1781
4. Bauer, J., C. E. Elger: Die akute Valproinsäure-Enzephalopathie. Akt. Neurol. 20 (1993) 16-21
5. Boxer, C. M., J. L. Herzberg, D. F. Scott: Has sodium valproate hypnotic effects? Epilepsia 17 (1976) 367-370
6. Calabrese, J. R., J. W. Goethe, A. Kayser, D. B. Marcotte: Adverse event in 583 valproate-treated patients. Depression 3 (1995/1996) 257-262
7. Clayton-Smith, J., D. Donnai: Fetal valproate syndrome. J. Med. Gen. 32 (1995) 724-727
8. Coulter, D. L., R. J. Allen: Hyperammonemia with valproic acid therapy. J. Pediatr. 98 (1981) 317-319
9. Coulter, D. L.: Carnitine, valproate, and toxicity. J. Child. Neurol. 6 (1991) 7-14
10. Dehling, E., P. Wolf: Reversible Demenz unter Valproattherapie. Epilepsie 88 (1988) 406-410
11. Delito, J. A.: The effect of valproate on bipolar spectrum temperamental disorders. J. Clin. Psychiatry 54 (1993) 300-304
12. del Real Francia, M. A., J. S. Martinez, J. V. Gamo, M. G. RodrÍguez-Magarinos: SÍndrome parkinsoniano inducido por valproato sódico. Neirologia 10 (9) (1995) 381-383
13. Dolman, C. L., R. A. Clasen, K. Dorini-Zis: Severe cerebral damage in ornithine transcarbamylase deficiency. Clin. Neuropathol. 7 (1988) 10-15
14. Duarte, J., S. Macias, F. Coria: Valproate-induced coma: case report and literature review. Ann. Pharmacother. 27 (5) (1993) 582 -583
15. Finkelstein, J. E., E. R. Hauser, C. O. Leonhard, S. W. Brusilow: Lateonset ornithine transcarbamoyl transferase deficiency in male patients. J. Pediatr. 117 (1990) 897-902
16. Frye, M. A., L. L. Altshuler, M. P. Szuba, N. N. Finch et al.: The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay. J. Clinical Psychiatry 57 (1) (1996) 17-21
17. Gerner, R. H., A. Stanton: Algorithm for patient management of acute manic states: lithium, valproate, or carbamazepine? J. Clin. Psychopharm. 12 (1) (1992) 57-63
18. Hering, R., A. Kuritzky: Sodium valproate has a prophylactic treatment of migraine: a double-blind study versus placebo. Cephalgia 12(1992) 81-84
19. Jensen, R., T. Brinck, J. Olesen: Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 44 (1994) 647-651
20. Joffe, R. T.: Valproate in bipolar disorder: the canadian perspective. Can. J. Psychiatry 38 (1993) S46-50
21. Kando, J. C., M. Tohen, J. Castillo, C. A. Zarate: The use of valproate in an elderly population with affective symptoms. J. Clin. Psychiatry 57 (6) (1996) 238-240
22. Kelley, R. I.: The role of carnitine supplementation in valproic acid therapy. Pediatrics 93 (6) (1994) 891-892
23. Kerleau, J. M., P. A. Bohu, F. Héron, N. D. Manchon: Encéphalopathie hyperammoniémique induite par le valproate de sodium. Rev. Méd. Interne 15 (1994) 363-364
24. Laub, M. C.: Nutritional influence on serum ammonia in young patients receiving sodium valproate. Epilepsia 27 (1986) 55-59
25. Leao, M.: Valproate as a cause of hyperammonemia in heterozygotes with ornithine-transcarbamylase deficiency. Neurology 45 (1995) 593-594
26. Lenn, N. J., W. G. Ellis, E. R. Washburn: Fatal hepatocerebral syndrome in siblings discordant for exposure to valproate. Epilepsia 31 (8) (1990) 578-583
27. Lott, A. D., S. L McElroy, M. A. Keys: Valproate in the treatment of behavioral agitation in elderly patients with dementia. J. Neuropsychiatry Clin. Neurosci. 7 (1995) 314-319
28. Marescaux, C., J. M. Bonardi, L. Rumbach, J. M. Warter et al.: Stupor due to sodium valproate. Immediate arousal after intravenous diazepam. Rev. Neurol. 137 (10) (1981) 635-638
29. Mathew, N. T., J. R. Saper, S. K. Silberstein et al.: Migraine prophylaxis with divalproex. Arch. Neurol. 52 (1995) 281-286
30. Matthei, A., G. Bernard: Encéphalopathie associée à une hyperammoniémie chez un patient alcoolique traité par le valproate de sodium. Gastroenterol. Clin. Biol. 17 (1993) 516
31. Mazure, C. M., B. G. Druss, J. S. Cellar: Valproate treatment of older psychotic patients with organic mental syndromes and behavioral dyscontrol. J. Am. Geriatr. Soc. 40 (1992) 914-916
32. McElroy, S. L., P. E. Keck, H. G. Pope, J. I. Hudson: Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J. Clin. Psychopharm. 12 (1) (1992) S42-S52
33. McElroy, S. L., P. E. Keck, H. G. Pope: Sodium valproate: its use in primary psychiatric disorders. J. Clin. Psychopharmacol. 7 (1987) 16-24
34. McElroy, S. L., P. E. Keck, S. P. Stanton: A randomized Comparison of divalproes oral loading versus haloperidol in the treatment of acute psychotic mania. J. Clin. Psychiatry 57 (4) (1996) 142-146
35. McLachlan, R. S.: Pseudoatrophy of the brain with valproic acid monotherapy. Can. J. Neurol. Sci. 14 (1987) 294-296
36. Miyazaki, C., K. Mattsuyama, M. Ichikawa: Effect of sodium valproate (VPA) on cerebral amino acids: mechanism of gamma-aminobutyric acid (GABA) elevation and possible causal relation of VPA-induced encephalopathy and glutamine level. Chem. Pharm. Bull. 36 (1988) 3589-3594
37. Murphy, J. V., K. Marquard: Asymptomatic hyperammonemia in patients receiving valproic acid. Arch. Neurol. 39 (1982) 591-592
38. Ohtani, Y., F. Endo, I. Matsuda: Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J. Pediatr. 101 (1982) 782-785
39. Papazian, O., E. Canizales, I. Alfonso, R. Archila: Reversible dementia and apparent brain atrophy during valproate therapy. Ann. Neurol. 38 (1995) 687-691
40. Sackellares, J. C., S. I. Lee, F. E. Dreifuß: Stupor following administration of valproic acid to patients receiving other antiepileptic drugs. Epilepsia 20 (1979) 697-703
41. Schöndienst, M., N. Füratsch: Akute Enzephalopathien nach Valproat-Reexposition. Epilepsie-Blätter 6 (1989) 31
42. Schöndienst, M.: Hirnatrophie durch Valproat? - 4 Fallberichte (Abstract). Epilepsie-Blätter 1 (1988) 23
43. Seidenberg, M., D. S. O'Learry, S. Berent, T. Boll: Changes in seizure frequency and test-retest scores on the Wechsler Adult Intelligence Scale. Epilepsia 22 (1981) 75-83
44. Settle, E. C.: Valproic acid-associated encephalopathy with coma. Am. J. Psychiatry 152 (8) (1995) 1236-1237
45. Sommerbeck, K. W., A. Theilgaard, K. E. Rasmussen, V. Lohren et al.: Valproate sodium: evaluation of so-called psychotropic effect. A controlled study. Epilepsia 18 (1977) 159-166
46. Sorensen, K. V.: Valproate: a new drug in migraine prophylaxis. Acta Neurol. Scand. 78 (1988) 346-348
47. Steinböck, H., B. Neophytou: Ein Fall einer Valproat-Encephalopathie mit Demenz-Syndrom bei einem 5 Jahre alten Knaben. Epilepsie-Blätter 6 (1993) 35
48. Steinhoff, B. J., S. R. G. Stodieck: Temporary abolition of seizure activity by flumenazil in a case of valproate-induced non-convulsive status epilepticus. Seizure 2 (1993) 261-265
49. Stephens, J. R., R. H. Levy: Effects of valproate and citrulline on ammonium-induced encephalopathy. Epilepsia 35 (1) (1994) 164-171
50. Stoll, A. L., C. A. Locke, A. Vuckovic, P. V. Mayer: Lithium associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series. J. Clin. Psychiatry 57 (8) (1996) 356-359
51. nd, San Francisco 1981
52. Takahashi, H., R. C. Koehler, S. W. Brusilow, R. J. Traystman: Inhibition of brain glutamine accumulation prevents cerebral edema in hyperammonemic rats. Am. J. Physiol. 261 (1991) H825-829
53. Tartara, A., R. Manni: Sodium valproate "encephalopathy": report of three cases with generalised epilepsy. Ital. J. Neurol. Sci. 6 (1985) 93-95
54. Thompson, P. J., M. R. Trimble: Sodium valproate and cognitive functioning in normal volunteers. Br. J. Clin. Pharmacol. 12 (1981) 819-824
55. Treem, W. R.: Inherited and acquired syndromes of hyperammonemia and encephalopathy in children. Semin. Liver. Dis. 14 (3) (1994) 236-258
56. Turnbull, D. M., D. J. Dick, L. Wilson et al.: Valproate causes metabolic disturbance in normal man. J. Neurol. Neurosurg. Psychiatry 49 (1986) 405-410
57. Visticot, F., G. Montreuil: Encéphalopathie stuporeuse induite par le valproate de sodium. Rev. Méd. Interna 15 (1994) 365-366
58. Zaret, B. S., R. A. Cohen: Reversible valproic acid-induced dementia: a case report. Epilepsia 27 (3) (1986) 234-240